Several studies have indicated that PAPP-A is a novel biomarker for plaque instability and inflammation, useful in early diagnosis, risk stratification, and prognostic prediction in patients with acute coronary syndrome (ACS) [30,31]. Here, PAPPA is linked to acute coronary syndrome.